Murray Katherine 4

What Happened
Katherine Murray, a director of Core Laboratories Inc. (CLB), converted/exercised derivative securities to acquire 8,069 shares on April 1, 2026 and simultaneously disposed of those 8,069 shares. On the same date she was reported as receiving 7,895 restricted shares. The reported price for these transactions is $0.00 on the Form 4 (no cash exercise price shown).

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 8, 2026 (filed 7 days after the transaction date; insiders generally must file within 2 business days, so this appears late).
• Exercise/conversion (code M): 8,069 shares acquired at $0.00 and 8,069 shares disposed at $0.00 (reported as simultaneous acquisition and disposition).
• Grant/award (code A): 7,895 restricted shares acquired at $0.00 (derivative).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F2 states certain Restricted Shares vested on April 1, 2026 (consistent with the conversion/disposition). F1 describes the 7,895 Restricted Shares as subject to a one-year vesting period ending April 1, 2027 and a deferral election; vested amounts are distributed as shares upon separation of service.
• No dollar proceeds or exercise price are shown on the Form 4 for these entries.

Context

• The conversion/exercise followed by an immediate disposition is commonly a cashless/settlement action (conversion of restricted stock units or exercise-and-sell), not necessarily a market-timing signal.
• The 7,895 shares are restricted and will vest subject to the terms noted (vesting April 1, 2027 and deferral provisions), so they do not represent immediately liquid stock.
• Filing timeliness: because the Form 4 was filed several days after the reported transactions, note the filing appears late relative to standard Section 16 filing deadlines.